Watanni tara bayan gabatar da shi a Amurka, Eisai da Leqembi na maganin Alzheimer na Biogen gamuwa gagarumin juriya a cikin karbuwarta, musamman saboda shakku tsakanin wasu likitoci game da ingancin maganin wannan cuta ta kwakwalwa.
Duk da kasancewarsa magani na farko da aka tabbatar don rage ci gaban cutar Alzheimer, shakku da ke tsakanin ma'aikatan kiwon lafiya game da darajar magance yanayin na zama babban cikas.
Kwararrun Alzheimer sun fara tsammanin ƙalubalen da ke da alaƙa da ƙa'idar neman Leqembi, wanda ya haɗa da ƙarin gwaje-gwajen bincike, jiko na wata-wata, da duban kwakwalwa na yau da kullun don saka idanu akan yiwuwar illa masu haɗari. Lallai, waɗannan buƙatun sun ba da gudummawa ga jinkirin shan maganin tun lokacin da Hukumar Abinci da Magunguna ta Amurka ta amince da ita, kamar yadda tattaunawa da likitocin jijiyoyin jiki 20 da likitocin geria suka tabbatar a yankuna daban-daban na Amurka.
A cewar kamfanin dillancin labaran reuters, likitoci bakwai sun bayyana shakkunsu na rubuta Leqembi, tare da nuna shakku kan ingancin maganin, tsadar sa, da kuma hadurran da ke tattare da shi. Bugu da ƙari, ƙungiyar ƙwararrun masana shida a fagen sun nuna cewa "nihilism na warkewa" - fahimtar cewa cutar Alzheimer wani yanayi ne wanda ba zai iya jurewa ba - yana da tasiri mai mahimmanci fiye da yadda ake tsammani wajen iyakance sha'awar likitocin kulawa na farko, likitocin geriatrics, da kuma likitocin kwakwalwa. Wannan shakku yana shafar shirye-shiryensu na tura marasa lafiya zuwa kwararrun ƙwaƙwalwar ajiya don yuwuwar jiyya tare da Leqembi.
Wasu masana sun ce rashin son wasu likitocin na iya samo asali ne daga dogon lokaci na shakku da ya haifar da hazakar da tasirin sinadarin beta amyloid na cutar Alzheimer don rage ci gaban cutar. Kafin a sami sakamako mai ƙarfafawa na gwajin Leqembi, da yawa a fannin likitanci sun ɗauki wannan jagorar bincike mara amfani.
Wasu kwararrun likitocin sun nuna damuwa game da illolin Leqembi, kamar kumburin kwakwalwa da zub da jini, baya ga farashin da ake kashewa tare da alamar farashin $26,500 na shekara-shekara, MRIs akai-akai, da infusions na wata-wata.
Leqembi shine maganin amyloid na farko da ya sami cikakkiyar amincewar FDA bayan ya nuna raguwar 27% na raguwar fahimi a tsakanin masu cutar Alzheimer na farko a lokacin gwaji na asibiti. Duk da burin farko na jinyar Amurkawa 10,000 a karshen watan Maris, 'yan dubbai ne kawai suka fara jinya a karshen watan Janairu, kamar yadda Eisai ya ruwaito, wanda kakakinsa ya ki bayar da sabbin alkaluma.
Ɗaukar sababbin magunguna, har ma waɗanda ba sa buƙatar canje-canje masu mahimmanci a aikin likita, yana da jinkirin gaske. Bincike ya nuna cewa yana iya ɗaukar matsakaicin shekaru 17 don binciken asibiti ya zama aikin yau da kullun. Cutar Alzheimer ta shafi Amurkawa sama da miliyan 6, amma duk da haka kasa da rabin likitocin jijiyoyin Amurka suna ba da shawarar Leqembi ga majiyyatan su, kamar yadda wani bincike na watan Janairu ta rayuwa. kimiyyar Mai binciken kasuwa Spherix Global Insights.
Written by Alius Noreika
